19/12/2022 Recombinant blood products for prophylaxis and management of haemophilia A and B
>
RThe Ministry of Health’s Drug Advisory Committee has recommended the following recombinant blood products for inclusion on the MOH Standard Drug List (SDL) for patients with haemophilia A (congenital factor VIII deficiency) and haemophilia B (congenital factor IX deficiency) in line with their registered indications when used as treatment and prophylaxis of bleeding episodes:
- Octocog alfa (Advate) 250 international units, 500 international units, 1000 international units and 1500 international units powder and solvent for solution for injection
- Rurioctocog alfa pegol (Adynovate) 250 international units, 500 international units, 1000 international units, 1500 international units, 2000 international units and 3000 international units powder and solvent for solution for injection
- Nonacog alfa (BeneFIX) 250 international units, 500 international units, 1000 international units and 2000 international units powder and solvent for solution for injection
NRBlood products that have not been recommended for subsidy due to unacceptable cost-effectiveness compared with subsidised alternatives are listed in the Annex.
The subsidy class and subsidy implementation dates (if applicable) for all blood products included in the review are provided in the Annex.